Document is current
Any future updates will be listed below
-
Authors
Marks, Jennifer A.
Wilgucki, Molly
Liu, Stephen V.
Reuss, Joshua E. https://orcid.org/0000-0002-6401-9080
- License Information
-
More Information
Article History
Accepted: 16 September 2022
First Online: 5 October 2022
Declarations
:
: JAM and MW declare no conflicts of interest. SVL reports grants (to institution) from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Gilead, Merck, Merus, Nuvalent, Pfizer, Rain Therapeutics, RAPT, Turning Point Therapeutics and consultant/advisory fees from Amgen, AstraZeneca, Bayer, Beigene, Blueprint, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead, Guardant Health, Janssen, Jazz Pharmaceuticals, Lilly, Merck/MSD, Novartis, Regeneron, Sanofi, Takeda, Turning Point Therapeutics. JER reports grants (to institution) from Genentech/Roche, Verastem, consultant/advisory fees from Oncocyte, Genentech/Roche, Sanofi/Genzyme, Personalis, and speaking fees from AstraZeneca.
: All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
